Drug–drug interaction between venetoclax, FLT-3 inhibitors, and azoles, which are all metabolized via CYP3A, should be deeply investigated in order to avoid possible unexpected toxicities in this population of AML patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.